Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.
Novo Nordisk leaps on new obesity drug data
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity but is coming under competitive pressure from rival therapies from Eli Lilly based on dual GIP/GLP-1 agonist tirzepatide.
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy. Read more here.
Novo Nordisk shares spike on results from experimental obesity drug trial
Investing.com - Copenhagen-listed shares in Novo Nordisk (CSE: NOVOb) surged on Friday after the Danish drugmaker said subcutaneous trials of its highly-anticipated experimental medicine amycretin showed patients using the treatment shed as much as an estimated 22% of their body weight.
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial.
Novo Nordisk shares jump on fresh trial results
Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss treatments.
Outsourcing-pharma2d
Novo Nordisk reports positive results for high-dose Wegovy formulation
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
STAT6d
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Novo Suffers Wegovy Trial Setback as US Plans to Cut Price
Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...
Crackdown on Ozempic, Wegovy Hits Thousands In Colorado
Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...
BioSpace2d
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...